ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is a specialty pharmaceutical company that develops, manufactures, and markets branded and generic prescription pharmaceuticals.
ANIP created a very attractive business model, in which it enters markets with few competitors allowing them to increase pricing and improve margins. Their current business model has proven to be highly successful as competition has left the market and they have improved pricing on their two biggest revenue driving products: EEMT & Opium Tincture.
In addition, ANIP has recently acquired 31 products from Teva, which I believe provide material upside from current levels. The acquisition has the added benefit of diversifying the company away from unapproved drugs. After talking to the CEO of ANIP, he stated that they...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|